The Antisense & RNAi Therapeutics Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Antisense & RNAi Therapeutics Market?
The market size of antisense and RNAi therapeutics has witnessed significant growth recently. The market value is estimated to increase from $1.75 billion in 2024 to $1.94 billion in 2025, growing at a compound annual growth rate (CAGR) of 11.2%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Antisense & RNAi Therapeutics Industry?
The Antisense & RNAi Therapeutics Global Market is predicted to grow to a value of $3.18 billion in 2029, with a compound annual growth rate (CAGR) of 13.1%.
Download Your Free Sample of the 2025 Antisense & RNAi Therapeutics Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Antisense & RNAi Therapeutics Market?
The key drivers in the antisense & rnai therapeutics market are:
• Enhanced access to healthcare services
• Rising incidence of cancer cases worldwide
• Increasing demand for antisense and RNAi therapeutics due to the COVID-19 pandemic
• Focus on researching and developing RNA therapeutics for orphan diseases
Global Market Segmentation: Identifying Major Antisense & RNAi Therapeutics Industry Segments
The antisense & RNAi therapeutics market covered in this report is segmented –
1) By Technology: RNA Interference, Antisense RNA
2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods
3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications
Pre-order the 2025 Antisense & RNAi Therapeutics Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Antisense & RNAi Therapeutics Market?
The key trends in the antisense & rnai therapeutics market are:
• There is a growing focus on research and development of RNA therapeutics for orphan diseases.
• The use of nanoparticles in therapeutics is a rising trend.
• The advancement and improvement of antisense and RNAi therapeutics is gaining momentum.
• Collaborations between companies for product innovation and revenue generation are becoming commonplace.
Who Are the Top Competitors & Leading Players in the Antisense & RNAi Therapeutics Market?
Major companies in the antisense & rnai therapeutics market are:
• Biogen Inc.
• Ionis Pharmaceuticals Inc.
• Alnylam Pharmaceuticals Inc.
• Arrowhead Pharmaceuticals Inc.
• Moderna Inc.
• Sanofi S.A.
• Dicerna Pharmaceuticals Inc.
• Arbutus Biopharma Corporation
• Acuitas Therapeutics
• Adhera Therapeutics Inc.
• EdiGene Inc.
• Sirnaomics Inc.
• Suzhou Ribo Life Science Co. Ltd
• Biocon Limited
• Quark Pharmaceuticals
• GlaxoSmithKline Plc
• Shanghai Junshi Biosciences Co. Ltd.
• AstraZeneca
• Benitec Biopharma Limited
• Silence Therapeutics
• Dynacure
• CN Bio Innovations
• Sarepta Therapeutics
• Mallinckrodt
• Regeneron Pharmaceuticals Inc.
• Alcyone Lifesciences Inc.
• Bio-Path Holdings Inc
• Calando Pharmaceuticals
• Enzon Pharmaceuticals Inc
• Celnova Pharma
• Pfizer Inc.
• Taiba Pharma
• Gen Ilaç ve Saglik Ürünleri A.S.
• Egypt Otsuka Pharmaceutical
Regional Dominance: Which Area Leads the Global Template Market?
North America was the largest region in the antisense & RNAi therapeutics market in 2024
